Peter J. Huwe

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

CADD v1.7: using protein language models, regulatory CNNs and other nucleotide-level scores to improve genome-wide variant predictions

High-throughput mutagenesis reveals functional determinants for DNA targeting by activation-induced deaminase

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma